KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $4.1 million.

  • Rigel Pharmaceuticals' Cash from Investing Activities fell 972.57% to -$33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.9 million, marking a year-over-year decrease of 1053.70%. This contributed to the annual value of $4.1 million for FY2024, which is 196.11% up from last year.
  • As of FY2024, Rigel Pharmaceuticals' Cash from Investing Activities stood at $4.1 million, which was up 196.11% from -$4.3 million recorded in FY2023.
  • Rigel Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $72.8 million during FY2022, with a 5-year trough of -$80.0 million in FY2021.
  • For the 3-year period, Rigel Pharmaceuticals' Cash from Investing Activities averaged around $24.2 million, with its median value being $4.1 million (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 300.65% in 2020, then plummeted by 268.62% in 2021.
  • Over the past 5 years, Rigel Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $47.5 million in 2020, then tumbled by 268.62% to -$80.0 million in 2021, then soared by 190.93% to $72.8 million in 2022, then plummeted by 105.90% to -$4.3 million in 2023, then surged by 196.11% to $4.1 million in 2024.